entertainment -WSS

entertainment

author：knowledge 2025-10-02 20:52:47 - browse：937

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Medicare has officially expanded its coverage policy for brain scans that detect a brain plaque associated with Alzheimer’s disease, the agency announced on Friday.

Amyloid PET scans are important tools to help determine whether patients with mild cognitive impairment are good candidates for new Alzheimer’s drugs, including Eisai and Biogen’s drug Leqembi, which means there will likely be an increase in demand for the scans as uptake increases.

Previously, Medicare limited coverage for the drug to patients enrolled in clinical studies, and only covered one scan in a patient’s lifetime. The new coverage policy removes those restrictions and delegates decisions about how many scans to cover to regional Medicare administrators.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Stories you might have missed in 2023: health, science, medicine

hotspot

focus

WSS

Nonprofit, backed by Microsoft, to certify AI tools in health care

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Profiling embryos to choose those with higher IQs is almost a reality

Arena BioWorks launches in Cambridge to speed drug discovery

FDA early review: GLP

STAT Virtual Event: JPM Recap, Live!

explore

entertainment

Wikipedia

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Heart disease in astronauts blamed on cosmic radiation

BioMarin wins approval for gene therapy to treat hemophilia A

Gene therapy denied for Afghan refugee whose father aided U.S.

ChatGPT in medicine: STAT answers readers' burning questions

Hospital chaplains balance Covid safety with patients’ spiritual needs

Drug repurposing or repositioning? The language matters

Late stage cancers on the rise after pandemic delayed screenings

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Group behind ProMed defends move to subscription

explore

Gene therapy denied for Afghan refugee whose father aided U.S.

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Group behind ProMed defends move to subscription

Chris Christie meets with Zelenskyy during Ukraine trip

JPM pitch from hospitals? Revenue streams outside of patient care

Life science postdocs should get big pay hike, NIH panel says

hotspot

focus

knowledge

explore